In brief: Biodiem; Avexa
Tuesday, 11 January, 2005
BioDiem (ASX:BDM) has received a US$1m signing-on payment, the first in a number of milestone payments due under its US$8m licence agreement with Akzo Nobel's Nobilon.
Avexa antibacterial studies confirmed
Maryland-based company ImQuest BioSciences has confirmed the activity of Avexa's (ASX: AVX) antibacterial compounds against vancomycin-resistant enterococci (VRE).
Avexa aims to have a lead compound in proof-of-concept models by the end of 2005.
Quitting smoking increases life expectancy even for seniors
Although the benefits of quitting smoking diminish with age, there are still substantial gains...
Stem cell transplants treat blindness in mini pigs
Scientists have successfully transplanted retinas made from stem cells into blind mini pigs,...
Sugary drinks raise cardiovascular disease risk, but occasional sweets don't
Although higher sugar intake raises your risk of certain cardiovascular diseases, consuming sweet...
